Why is Aarti Pharma falling/rising?

As of 25-Jul, Aarti Pharmalabs Ltd is experiencing a slight increase in its stock price, currently at 940.05, reflecting a change of 2.05 or 0.22% upward. The stock is currently 3.35% away from its 52-week high of Rs 971.5 and is performing in line with its sector. While the stock has shown a positive return of 8.59% over the past month and an impressive 60.14% over the past year, it has seen a decline of 0.73% over the past week. The company benefits from a strong ability to service debt, evidenced by a low Debt to EBITDA ratio of 0.63 times, and positive financial results, including a record PBT growth of 41.7% and net sales reaching Rs 563.78 cr. However, concerns arise from a poor long-term growth rate in net sales and a reduction in promoter confidence, as they have decreased their stake by 0.57% in the last quarter.
In the broader market context, Aarti Pharmalabs Ltd has outperformed the benchmark, as the BSE500 has generated negative returns of -0.19% over the past year, while Aarti has achieved a remarkable 60.14% return. Despite the stock's recent performance, the decline in investor participation, with a 22.65% drop in delivery volume against the 5-day average, may indicate some caution among investors. Additionally, while the stock is trading above its longer-term moving averages, it is below the 5-day moving average, suggesting mixed short-term momentum. Overall, the stock's positive performance relative to the market, combined with strong financial metrics, supports its recent rise, although concerns about long-term growth and promoter confidence may temper investor enthusiasm.